Challenge trials for vaccines will be much less risky and controversial if they have a therapeutic that could mitigate the risk for participants. It gives the U.K. more incentive to be creative about therapeutics. We shall see....

Quote:
https://www.msn.com/en-us/health/medical/uk-l...li=BBnb7Kz

Now, will they extend this to mAbs? Is this where NP is pinning his hopes for speeding up our enrollment? Push it, Nader! Push it!!

Read More: https://investorshangout.com/post/newpost/605...z6bQStI61p